3. Myeloproliferative Neoplasms

  1. Hussain I. Saba MD, PHD3 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH4
  1. Ruben A. Mesa1 and
  2. Ayalew Tefferi2

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch3

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Mesa, R. A. and Tefferi, A. (2011) Myeloproliferative Neoplasms, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch3

Editor Information

  1. 3

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 4

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. 1

    Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA

  2. 2

    Department of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016



  • myeloproliferative;
  • polycythemia vera;
  • essential thrombocythemia;
  • primary myelofibrosis;
  • JAK2


The therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at an exciting crossroads. On the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The discovery of the JAK2V617F and related mutations in ET, PV, and PMF has ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis, and the risks and benefit of each therapeutic modality.